Journal of Bioequivalence & Bioavailability

Pharmaceutical and immunological evaluation of ligand grafted pegylated PLGA nanoparticles for oral vaccine delivery

3^rd World Congress Bioavailability & Bioequivalence

March 26-28, 2012 Marriott Hotel & Convention Centre, Hyderabad, India

B.Pragana, Rajendren Jagathesh Chandra Bose, P.Vijiyalaxmi and J.Balamurugan

Posters: J Bioequiv Availab

Abstract:

N anotechnology has been applied to improve vaccine delivery and to develop a nano-sized vaccine delivery system. Nanoparticles have been developed as an important strategy to deliver biomacromolecules such as antigens or DNA. In fussy, polymeric nanoparticles with entrapped antigens represent an exciting approach to sustain release of vaccine antigens and to optimize the desired immune response via selective targeting of the antigen to the specified cells like M cells. The efficiency of orally delivered vaccines, PEGylated PLGA-based nanoparticles displaying ligand molecules at their surface were designed to target human M cells. In this research we were attempt to prepare ligand grafted PEGylated PLGA nanoparticles by double emulsion method, and the M cell targeting ligand grafting was performed by photografting which covalently linked with ligand mainly on the PEG moiety of the PCL?PEG, included in the formulation. Similarly non-targeted formulations with size and zeta potential adapted to M cell uptake and stable in gastro-intestinal fluids, were developed. The physio - chemical parameters like Zeta potentials, particle size and entrapment efficiency, Antigen integrity was performed for PEGylated PLGA nanoparticles. In vitro and In vivo studies were performed to evaluate the oral vaccine (M cell targeting and immunological efficiency of nanoparticles). From the results we strongly demonstrated that the NP transport by an in vitro model of the human Follicle associated epithelium (co-cultures) was largely increased as compared to mono-cultures (Caco-2 cells). M cell targeting ligand grafting nanoparticles significantly increased their transport by co-cultures, due to interactions between the ligand and the β1 intregrins detected at the apical surface of co-cultures. In vivo studies demonstrated that ligand grafted PEGylated PLGA nanoparticles particularly concentrated in M cells. In conclusion, OVA-loaded ligand grafted PEGylated PLGA nanoparticles were orally administrated to mice and evaluated for its induction of an IgG response, and related an immune response after oral delivery.